[1]刘博文,侯训博,李映辰,等.纳米材料在肝癌介入治疗中的研究进展[J].中国材料进展,2026,45(06):533-542.[doi:10.7502/j.issn.1674-3962.202603001]
　IU Bowen,HOU Xunbo,LI Yingchen,et al.Research Progress on Nanomaterials in Interventional Therapy for Hepatocellular Carcinoma[J].MATERIALS CHINA,2026,45(06):533-542.[doi:10.7502/j.issn.1674-3962.202603001]
点击复制

纳米材料在肝癌介入治疗中的研究进展()

中国材料进展[ISSN:1674-3962/CN:61-1473/TG]

卷:
45
期数:
2026年06
页码:
533-542
栏目:
出版日期:
2026-05-31

文章信息/Info

Title:
Research Progress on Nanomaterials in Interventional Therapy for Hepatocellular Carcinoma
文章编号:
1674-3962(2026)06-0533-10
作者:
刘博文; 侯训博; 李映辰; 刘雪松; 张海翔; 李文博; 尹立楠
哈尔滨医科大学附属肿瘤医院 介入科，黑龙江 哈尔滨 150000
Author(s):
IU Bowen;  HOU Xunbo;  LI Yingchen;  LIU Xuesong; ZHANG Haixiang;  LI Wenbo;  YIN Linan
Interventional Department, Harbin Medical University Cancer Hospital, Harbin 150000, China
关键词:
纳米材料; 经动脉化疗栓塞术; 肝细胞癌; 多功能; 抗肿瘤机制
Keywords:
nanomaterials;  transarterial chemoembolization;  hepatocellular carcinoma; multifunctionality;  antitumor mechanisms
分类号:
R735.7
DOI:
10.7502/j.issn.1674-3962.202603001
文献标志码:
A
摘要:
肝细胞癌具有较高的发病率与死亡率，作为全球高发的恶性肿瘤，多数患者确诊时已处于中晚期，易错失根治性治疗时机。对于中晚期不可切除的肝细胞癌患者，经动脉化疗栓塞术是核心的介入治疗手段，也是改善患者生存预后的关键方式，而栓塞材料的选择是治疗的核心环节，其性能直接决定肿瘤血管栓塞的彻底性、化疗药物的释放效率及治疗的安全性。传统栓塞材料存在栓塞不完全、药物释放不稳定、易诱发缺氧性复发等固有局限，这类问题极大限制经动脉化疗栓塞术的临床疗效。近年来，随着与材料科学和纳米技术的深度融合，用于肝癌介入治疗的纳米材料正向集诊断、治疗、监测于一体的精准治疗平台演进。首先围绕各类纳米材料的结构特性、载药栓塞机制及相关基础研究与临床前研究成果进行系统阐述；其次，详细介绍纳米材料药物负载与靶向递送、对肿瘤微环境及外界刺激的响应能力，以及影像引导的多功能整合能力；最后，明确用于肝癌介入治疗的纳米材料技术现存的挑战与未来发展方向，为该领域的临床实践优化与科研创新提供参考。
Abstract:
Hepatocellular carcinoma is a highly prevalent malignant tumor worldwide with high morbidity and mortality. Most patients are diagnosed at the intermediate and advanced stages, thus missing the opportunity for radical treatment. For patients with unresectable intermediate and advanced hepatocellular carcinoma, transarterial chemoembolization serves as the core interventional therapeutic modality and a crucial approach to improve patients survival and prognosis. As a key link in treatment, the performance of embolic materials directly determines the completeness of tumor vascular embolization, the release efficiency of chemotherapeutic drugs and the safety of treatment. Traditional embolic materials have inherent limitations such as incomplete embolization, unstable drug release and susceptibility to inducing hypoxic tumor recurrence, which greatly restrict the clinical efficacy of transarterial chemoembolization. In recent years, with the deep integration of materials science and nanotechnology, nanomaterials are evolving into precision therapy platforms with integrating diagnosis, treatment and monitoring. This paper first systematically elaborates the structural characteristics, drugloaded embolization mechanisms of various nanomaterials, as well as the progress of relevant basic and preclinical studies. Secondly, it details the multifunctional integration capabilities of nanomaterials in drug loading and targeted delivery, responsiveness to the tumor microenvironment and external stimuli and imaging-guiding. Finally, it clarifies the existing challenges and future development directions of nanomaterial technology for hepatocellular carcinoma interventional therapy, providing a reference for the optimization of clinical practice and scientific innovation in this field.

备注/Memo

备注/Memo:
收稿日期：2026-03-03修回日期：2026-04-23 第一作者：刘博文，男，1999年生，硕士研究生 通讯作者：尹立楠，男，1987年生，副主任医师，硕士生导师， Email:yinlinan3010@hrbmu.edu.cn
更新日期/Last Update: 2026-06-10